CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia
New England Journal of Medicine · 15.01.2026 · 394 (3) · 253-267
DOI: 10.1056/nejmoa2509820 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 15.01.2026. Verfasst von Ruonan Li und 37 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute …. Hauptthemen laut MEDLINE: Anemia, Hemolytic, Autoimmune, Antigens, CD19, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: State Key Laboratory of Experimental Hematology, Chinese Academy of Medical Sciences, Natural Science Foundation of Tianjin City.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical…
- Tianjin Institutes of Health Science, Tianjin, China.
- Red Blood Cell Diseases Center and Regenerative Medicine Clinic, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
- Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.
- Juventas Cell Therapy, Tianjin, China.
- Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai.
ORCID-Profile: Lele Zhang
Förderung
- State Key Laboratory of Experimental Hematology
- Chinese Academy of Medical Sciences
- Natural Science Foundation of Tianjin City
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- State Key Laboratory of Experimental Hematology Research Grant
- Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences
- Natural Science Foundation of Tianjin
Zitieren
APA
Li, R., Pan, H., Zhang, L., Ma, J., Li, W., Gao, Z., Fang, L., Tian, L., Shen, Y., Yang, F., Zhao, J., Nie, N., Li, J., Wang, W., Pan, X., Lian, Y., Li, X., Peng, G., Li, L., …, & Shi, J. (2026). CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia. New England Journal of Medicine, 394(3), 253-267. https://doi.org/10.1056/nejmoa2509820
Vancouver
Li R, Pan H, Zhang L, Ma J, Li W, Gao Z, et al. CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia. New England Journal of Medicine. 2026;394(3):253-267. doi:10.1056/nejmoa2509820
BibTeX
@article{Li2026,
author = {Li, Ruonan and Pan, Hong and Zhang, Lele and Ma, Jiaxiu and Li, Weiwang and Gao, Zhen and Fang, Liwei and Tian, Linzhu and Shen, Yucan and Yang, Fei and Zhao, Jingyu and Nie, Neng and Li, Jianping and Wang, Wenyan and Pan, Xinan and Lian, Yu and Li, Xingxin and Peng, Guangxin and Li, Liyun and Yu, Xiao and Xu, Chun and Liu, Yanjie and Kuang, Zhexiang and Huang, Jinbo and Zhao, Xin and Ge, Meili and Liu, Lijun and Chen, Shuo and Feng, Yi and Chang, Alex H and Deng, Biping and Dai, Min and Huang, Lifang and Lv, Lulu and Zheng, Yizhou and Luo, Yuechen and Xiong, Haiqing and Shi, Jun},
title = {CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {3},
pages = {253--267},
doi = {10.1056/nejmoa2509820}
}
EUVIMED